A new depression scale designed to be sensitive to change
- PMID: 444788
- DOI: 10.1192/bjp.134.4.382
A new depression scale designed to be sensitive to change
Abstract
The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described. Ratings of 54 English and 52 Swedish patients on a 65 item comprehensive psychopathology scale were used to identify the 17 most commonly occurring symptoms in primary depressive illness in the combined sample. Ratings on these 17 items for 64 patients participating in studies of four different antidepressant drugs were used to create a depression scale consisting of the 10 items which showed the largest changes with treatment and the highest correlation to overall change. The inner-rater reliability of the new depression scale was high. Scores on the scale correlated significantly with scores on a standard rating scale for depression, the Hamilton Rating Scale (HRS), indicating its validity as a general severity estimate. Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change. The practical and ethical implications in terms of smaller sample sizes in clinical trials are discussed.
Similar articles
-
Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline.Br J Clin Pharmacol. 1978;5 Suppl 1(Suppl 1):77S-80S. Br J Clin Pharmacol. 1978. PMID: 341948 Free PMC article. Clinical Trial.
-
Relative speed of onset of the antidepressant effect of maprotiline.Clin Ther. 1981;3(5):374-81. Clin Ther. 1981. PMID: 7471133
-
Comparison of the efficacy of sustained-release amitriptyline with maprotiline in the treatment of depressive illness.Curr Med Res Opin. 1980;6(8):534-9. doi: 10.1185/03007998009109483. Curr Med Res Opin. 1980. PMID: 7389384 Clinical Trial.
-
Maprotiline, nomifensine, mianserin, zimelidine: a review of antidepressant efficacy in in-patients.Neuropharmacology. 1980 Dec;19(12):1185-90. doi: 10.1016/0028-3908(80)90199-9. Neuropharmacology. 1980. PMID: 6449677 Review. No abstract available.
-
A risk-benefit assessment of mirtazapine in the treatment of depression.Drug Saf. 1997 Oct;17(4):251-64. doi: 10.2165/00002018-199717040-00005. Drug Saf. 1997. PMID: 9352961 Review.
Cited by
-
Psychometric properties of the ultra-brief self-report Patient Health Questionnaire-4 (PHQ-4) to assess anxiety and depression in Arabic-speaking adults.BMC Psychiatry. 2024 Jul 30;24(1):537. doi: 10.1186/s12888-024-05978-8. BMC Psychiatry. 2024. PMID: 39080577 Free PMC article.
-
Visual system structural and functional connections during face viewing in body dysmorphic disorder.bioRxiv [Preprint]. 2024 Jul 16:2024.07.12.603273. doi: 10.1101/2024.07.12.603273. bioRxiv. 2024. PMID: 39071433 Free PMC article. Preprint.
-
Psychometric Properties of the Korean Version of THINC-integrated Tool (THINC-it-K): A Tool for Screening Assessment of Cognitive Function in Patients with Major Depressive Disorder.Clin Psychopharmacol Neurosci. 2024 Aug 31;22(3):458-465. doi: 10.9758/cpn.23.1135. Epub 2023 Nov 30. Clin Psychopharmacol Neurosci. 2024. PMID: 39069685 Free PMC article.
-
No Evidence of Gut Microbiota Alteration in Psoriasis Patients Switching to Brodalumab after Loss of TNFα Inhibition Effect.Int J Mol Sci. 2024 Jul 15;25(14):7745. doi: 10.3390/ijms25147745. Int J Mol Sci. 2024. PMID: 39062988 Free PMC article.
-
Cope PPA-Adaptation of the Biographic-Narrative Approach for Persons with Primary Progressive Aphasia: Protocol for Clinical Trial Design.Brain Sci. 2024 Jul 11;14(7):692. doi: 10.3390/brainsci14070692. Brain Sci. 2024. PMID: 39061432 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
